Behavioral Counseling and Varenicline Treatment for Smoking Cessation

Abstract

Background-Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence.

Adherence to Varenicline in the COMPASS Smoking Cessation Intervention Trial

“…This trial compared the effectiveness of three modalities of a behavioral smoking cessation program when combined with varenicline use among smokers seeking treatment at a large health care organization. When varenicline treatment was integrated with either Web-based counseling, proactive phone-based counseling, or integrated phone and Web counseling, no significant differences in 6-month abstinence rates were found (Swan et al, 2010). Abstinence rates in this real-world effectiveness study were high (31%-34%) and similar to rates seen in varenicline clinical trials when the medication was combined with in-person counseling (Swan et al, 2010).…”

Organic Cation Transporter Variation and Response to Smoking Cessation Therapies

“…[44][45][46] These were treatment efficacy trials, comparing pharmacotherapies with either group or individual behavioral counseling sessions, 40,[42][43][44][45][46] or, a behavioral effectiveness trial comparing behavioral therapy delivery modes. 41 For this analysis, we nominated SNPs (Supplementary Table 4) based on one or more of the following criteria: (a) evidence for genome-wide association with a metabolic phenotype, (b) non-synonymous substitutions or variants likely to be functional, (c) evidence from a candidate gene association study of response to smoking cessation therapies, 10 (d) genotypes from our database, 46 and (e) minor allele frequency ≥ 0.01 in 1000 Genomes or HapMap Utah residents with ancestry from northern and western Europe (CEU). Seventy-seven SNPs at the three gene loci (±50kbp) were previously chosen for Illumina GoldenGate® assay synthesis, 68 were genotyped and met quality control criteria, and 674 SNPs were imputed as described 47 in six randomized controlled trials.…”

“…These trials were conducted in Washington DC and Philadelphia PA, 40 Washington, 41 California, 42,43 and Wisconsin. [44][45][46] These were treatment efficacy trials, comparing pharmacotherapies with either group or individual behavioral counseling sessions, 40,[42][43][44][45][46] or, a behavioral effectiveness trial comparing behavioral therapy delivery modes.…”

“…Seventy-seven SNPs at the three gene loci (±50kbp) were previously chosen for Illumina GoldenGate® assay synthesis, 68 were genotyped and met quality control criteria, and 674 SNPs were imputed as described 47 in six randomized controlled trials. [41][42][43][44][45][46] We restricted our analyses to self-identified European ancestry individuals to reduce potential heterogeneity of genetic effects across continental population groups. Assessment of genotype completion rates, genotyped or imputed genotypes from nominated or proxy SNPs, linkage disequilibrium, and minor allele frequencies reduced this to six SNPs with genotyped genotype data (Table 2 and Supplementary Table 4).…”

Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study

“…Potential participants were identified based on electronic health records (Phases 1 and 2) and a subset of participants in a previous smoking cessation study (Phase 2; Swan et al, 2010), who had been previously genotyped and provided consent to be recontacted. Potential participants were mailed an invitation letter, contacted by phone, and screened for eligibility.…”